Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
- Conditions
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02608034
- Locations
- 🇮🇱
Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, Israel
🇰🇷Samsung Medical Center; Gastroenterology, Seoul, Korea, Republic of
🇷🇺FSBSI "N. N. Blokhin Russian Cancer Research Center", Moscow, Russian Federation
Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 18
- Registration Number
- NCT02602509
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
EVRIOS : Comparative Evaluation of Low Versus High Doses of Rifampicin
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 544
- Registration Number
- NCT02599493
- Locations
- 🇫🇷
La Roche sur Yon hospital, La Roche sur Yon, France
🇫🇷Clinique du Parc et Hôpital Jean Mermoz, Lyon, France
🇫🇷Rennes university hospital, Rennes, France
A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- St George's, University of London
- Target Recruit Count
- 672
- Registration Number
- NCT02581527
- Locations
- 🇺🇬
Epicentre, Mbarara, Uganda
🇵🇪Hospital Nacional Dos de Mayo, Lima, Peru
🇳🇵GENETUP, National Anti-TB Association, Kathmandu, Nepal
Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 24
- Registration Number
- NCT02576366
- Locations
- 🇧🇪
University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 60
- Registration Number
- NCT02563327
- Locations
- 🇺🇬
Mulago Hospital, Kampala, Uganda
Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia
- Conditions
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- University of Giessen
- Target Recruit Count
- 147
- Registration Number
- NCT02554318
Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Johns Hopkins University
- Registration Number
- NCT02547116
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8
- Conditions
- Interventions
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- University Medicine Greifswald
- Target Recruit Count
- 19
- Registration Number
- NCT02507167
- Locations
- 🇩🇪
Department of Clinical Pharmacology, Greifswald, Germany
A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Nivalis Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02500667
- Locations
- 🇺🇸
St. Anthony's Medical Plaza 1, Lakewood, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.